• Home
• About Makaira
• Investment Team
• Partner Resources
• Portfolio Companies
• Submit Your Executive Summary
• Contact Us
• News
  • Cardiosolutions names Dr. Lars Svensson Chief Surgical Officer
  • Five Questions With: Dr. A. Robert Buonnano
  • Knees In Need
  • CE Mark approval for UniCAP knee
  • Spirus Medical Announces 510(k) Clearance from FDA for Expanded Use of Endo-Ease(R) Discovery SB(TM)
  • Cardiosolutions Raises $7 Million for Spacer Technology to Mitigate Mitral Regurgitation
  • STDMed Inc. Brings Forward Fourth Startup, Closes Series A Financing for Cardiosolutions
  • Spirus gets $8.5M Series B for med devices
  • Frost & Sullivan Names Spirus Medical 2007 U.S. Endoscopy Entrepreneurial Company of the Year
  • Spinoff cycle: STD Med builds devices, startups
  • Arthrosurface Raises $10.5 million in 4th Round of Preferred Equity Financing
  • STD Manufacturing Announces Sale Of AngioLink Corporation
  • Medtronic Acquires Angiolink Corporation, Maker Of Wound Closure Device For Vascular Procedures

STD Manufacturing Announces Sale Of AngioLink Corporation

STOUGHTON, Mass., Nov. 19 /PRNewswire/ -- STD Manufacturing, Inc., an OEM medical device engineering and manufacturing company headquartered in Stoughton, Massachusetts, announced today that AngioLink Corporation, the first company that was incubated at STD, was acquired by Medtronic, Inc. AngioLink Corporation is a medical device company developing wound management and wound closure products, including the EVS(TM) Vascular Closure System, which received FDA PMA approval last week. AngioLink's EVS system is a unique, arterial stapling device for use closing holes and punctures made in arteries in connection with the over 8 million catheter-based surgical procedures such as angioplasty, angiograms and the like performed each year. The EVS is also approved for sale in Europe and Canada. AngioLink was incubated at STD before being separated into an independent company several years ago, and STD will continue to provide manufacturing and assembly services for the EVS system.

"Five years ago we decided to develop a better femoral artery closure device to address the enormous unmet needs in this market. It is especially gratifying to start from scratch, develop a great product, form a company, get FDA approval and now join forces with a company of Medtronic's stature," said Steven Tallarida, President of STD Manufacturing, Inc.

"On the heels of the tremendous results obtained in our clinical trial and the receipt of our PMA from the FDA, we are now part of the pre-eminent medical technology company in the world. This will accelerate the introduction of the EVS system in all the major medical device markets," said James Lousararian, former President and CEO of AngioLink. "Being nurtured at STD and supported by STD through the many stages of development reduced the cost and time of development immeasurably."

STD Manufacturing, Inc., headquartered in Stoughton, Massachusetts, is a leading OEM medical device engineering and manufacturing company. In addition to AngioLink, STD started and incubated the HemiCAP(TM) articular cartilage resurfacing system owned by Arthrosurface Incorporated (http://www.arthrosurface.com/ ). STD is ISO 9001 and 13485, and QSR compliant.

CONTACT: Andrea Patisteas, V.P. Marketing, STD Manufacturing, Inc., +1-781-828-4400

For more on STD Med Inc., visit http://www.stdmed.com